APRI (Aprinoia Therapeutics) Short-Term Debt: $18.57 Mil (As of Dec. 2023)


What is Aprinoia Therapeutics Short-Term Debt?

Aprinoia Therapeutics APRI Short-Term Debt is $18.57 Mil as of Dec. 2023.

Aprinoia Therapeutics's Short-Term Debt for the quarter that ended in Dec. 2023 was $18.57 Mil.

Aprinoia Therapeutics's quarterly Short-Term Debt increased from Dec. 2022 ($2.54 Mil) to Jun. 2023 ($15.48 Mil) and increased from Jun. 2023 ($15.48 Mil) to Dec. 2023 ($18.57 Mil).

Aprinoia Therapeutics's annual Short-Term Debt increased from Dec. 2021 ($0.79 Mil) to Dec. 2022 ($2.54 Mil) and increased from Dec. 2022 ($2.54 Mil) to Dec. 2023 ($18.57 Mil).

Aprinoia Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Aprinoia Therapeutics Short-Term Debt Related Terms

Aprinoia Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Short-Term Debt Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Short-Term Debt
0.79 2.54 18.57

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt 0.79 0.00 2.54 15.48 18.57
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $18.57 Mil mean?
Aprinoia Therapeutics (APRI) has a Short-Term Debt of $18.57 Mil as of Dec. 2023.
Is Aprinoia Therapeutics' Short-Term Debt too high?
Aprinoia Therapeutics' current Short-Term Debt is $18.57 Mil.
How does Aprinoia Therapeutics' Short-Term Debt compare to ?
Aprinoia Therapeutics' Short-Term Debt of $18.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Aprinoia Therapeutics's current Short-Term Debt is $18.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Short-Term Debt of $18.57 Mil. The current Short-Term Debt is $18.57 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Short-Term Debt is $18.57 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.